Iradimed (IRMD) Releases FY18 Earnings Guidance

Iradimed (NASDAQ:IRMD) updated its FY18 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $0.33-$0.38 for the period, compared to the Thomson Reuters consensus estimate of $0.35. The company issued revenue guidance of $29.3-$30.0 million, compared to the consensus revenue estimate of $29.70 million.Iradimed also updated its Q1 guidance to $0.06-$0.07 EPS.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Iradimed from a buy rating to a hold rating in a research report on Saturday. Roth Capital assumed coverage on shares of Iradimed in a research report on Tuesday, October 31st. They issued a buy rating and a $16.00 price objective for the company. Finally, Credit Suisse Group assumed coverage on shares of Iradimed in a research report on Monday, November 27th. They issued a buy rating and a $19.00 price objective for the company. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $17.33.

Shares of Iradimed (IRMD) opened at $15.05 on Tuesday. Iradimed has a 52-week low of $7.85 and a 52-week high of $15.85. The stock has a market cap of $158.33, a PE ratio of 115.78 and a beta of 1.45.

Iradimed (NASDAQ:IRMD) last released its earnings results on Tuesday, February 6th. The medical equipment provider reported $0.10 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.08. Iradimed had a net margin of 6.51% and a return on equity of 4.58%. The firm had revenue of $6.70 million during the quarter, compared to the consensus estimate of $6.72 million. During the same period in the prior year, the firm earned $0.11 EPS. The company’s revenue was up 11.9% compared to the same quarter last year. equities analysts predict that Iradimed will post 0.05 EPS for the current year.

In other news, Director Monty K. Allen sold 1,898 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $13.95, for a total transaction of $26,477.10. Following the completion of the transaction, the director now directly owns 9,062 shares of the company’s stock, valued at approximately $126,414.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 60.10% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Iradimed (IRMD) Releases FY18 Earnings Guidance” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/06/iradimed-irmd-releases-fy18-earnings-guidance.html.

Iradimed Company Profile

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply